Vascular Endothelial Growth Factor Levels in Ectopic Pregnancy

Overview

The aim of this study is to determine plasma Vascular Endothelial Growth Factor level and change in patient with ectopic pregnancy who needs to surgical treatment. Patient with ectopic pregnancy diagnosed and treated with medically or surgically will be included in the study. This is an observational study.The plasma Vascular Endothelial Growth Factor level will be measured first day and two day after the diagnosis of ectopic pregnancy.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: February 2013

Detailed Description

This study is a prospective, observational, single-center study. Ethical approval was obtained from the Institutional Review Board. This study will be completed with 30 patients with ectopic pregnancy. An intervenous cannula will be centrifuged for 15 minutes at 1000 g within 30 minutes of collection. Aliquots of plasma will be added to eppendorf tubes and stored at -20°C. Plasma Vascular Endothelial Growth Factor levels will be measured using a Human VEGF-A Platinum ELISA kit (bioscience company, Catalog No: 00122, Santa Clara, California, USA). All assays will be performed according to the manufacturer's instructions. The test kit sensitivity is 2.5 pg/ml. Intracycle variability is %4-6, intercycle variability is %8-10.

Arms, Groups and Cohorts

  • Follow-up or medical treatment.
    • medical treatment
  • Surgical treatment
    • Surgical treatment

Clinical Trial Outcome Measures

Primary Measures

  • The primary Outcome Measure of this study is to determine plasma Vascular Endothelial Growth Factor cut-off level in patient with ectopic pregnancy who needs to surgical treatment.
    • Time Frame: 3-4 months

Participating in This Clinical Trial

Inclusion Criteria

  • Patients who suspected ectopic pregnancy Exclusion Criteria:

  • hemodynamically unstable patient – healthy pregnancy (a healthy increase in ß HCG) – missed abortion – incomplete abortion – The patient who need immediate surgical treatment

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 46 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Bagcilar Training and Research Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • TANER A USTA, M.D., Principal Investigator, Bagcilar Training and Research Hospital, Istanbul, Turkey.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.